IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) November 11, 2014 -- President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.
Proove has been presenting research and data at industry conferences across the country this past year, demonstrating the value and innovation their genetic testing creates in the field of pain medicine. The aim of the conference is to provide attendees with insight from key thought leaders in the industry, and as such, Mr. Meshkin provided an illustrative dialogue on how Proove’s proprietary genetic testing services have been able to assist physicians better understand their patients’ needs based off their genetic profiles.
“It is an incredibly exciting time in healthcare because of the advances the scientific community has been able to achieve with the help of genetic analysis and testing,” stated Meshkin. “Proove Biosciences has been at the front of this industry, providing physicians with the tools and science necessary to better understand the complexities of their patients’ pain, and prescribe treatments that meet their personal needs. The Pain Therapeutics Summit was and ideal medium to illustrate the value that genetic testing can offer in treating and managing patient pain.”
About Proove Biosciences
Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.
Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).
Nicole McMillan, Proove Biosciences, http://www.proovebio.com, +1 855-776-6832 Ext: 716, [email protected]